The small GTPase Rho is important for cell cycle progression and Ras transformation in ®broblasts. However, it is unclear whether Rho is needed for proliferation in other cell types, and its targets in promoting normal cell cycle progression are unknown. Here, we demonstrate that Rho is required for G1 to S progression in MCF10A mammary epithelial cells, both in response to EGF and in response to oncogenic Ras. We describe two eects of Rho, the repression of p21 CIP1 and the induction of cyclin D1, that may underlie its role in promoting S phase entry. The Rho inhibitor, C3 exotransferase, induced p21 CIP1 both in EGF-stimulated and V12Ras-expressing cells. In addition, C3 blocked EGF-stimulated cyclin D1 promoter activity whereas V14RhoA induced the cyclin D1 promoter and cooperated with V12Ras in cyclin D1 induction. Finally, a high proportion of cells co-expressing V14RhoA and V12Ras displayed lobulated, polyploid nuclei that were actively synthesizing DNA. Our results demonstrate that Rho plays a fundamental role in promoting Ras-dependent S phase entry in mammary epithelial cells, whether in response to normal or oncogenic signaling, and indicate that in cells expressing oncogenic Ras, the activation of Rho diminishes p21 CIP1 expression, increases cyclin D1 promoter activity, and uncouples DNA synthesis from mitosis.
Introduction
The Rho family of guanosine triphosphatases (GTPases), including the Rho, Rac and Cdc42 subfamilies, are molecular switches that regulate signal transduction networks in eukaryotic cells (Van Aelst and D'Souza-Schorey, 1997) . These networks respond to changes in the external environment, orchestrating the cellular response to chemoattractants, morphogens, and mitogens as well as to physical or chemical stresses. Although Rho GTPases are best characterized as regulators of the actin cytoskeleton (Nobes and Hall, 1995) , their importance in cell proliferation control and oncogenic transformation has emerged as a key theme in describing their cellular function. A role in regulating the mitogenic response to serum was established by the ability of Rho family proteins to regulate serum-induced cell cycle progression (Olson et al., 1995; Yamamoto et al., 1993) . Ectopic overexpression of constitutively active mutants of RhoA, Rac1, and Cdc42 forced quiescent ®broblasts to reenter the cell cycle while C3 exotransferase, an inhibitor of RhoA, B, and C, and dominant interfering mutants of Rac1 and Cdc42 blocked serum-induced DNA synthesis. In addition to being needed for proliferation in non-transformed cells, Rho family proteins are necessary for oncogenic (V12) Rasmediated transformation. This was evidenced by the ability of active mutants of RhoA or B, Rac1, and Cdc42 to cooperate with V12Ras in focus formation and anchorage-independent growth assays, and by the ability of dominant negative mutants of these proteins to inhibit V12Ras-induced transformation (KhosraviFar et al., 1997; Prendergast et al., 1995; Qiu et al., 1997 Qiu et al., , 1995a . Notably, only RhoA, not RhoB, Rac1, or Cdc42, was able to block the transforming activity of Raf as well as that of V12Ras (Qiu et al., 1995b) . Since the oncogenic signal of Raf is transmitted through Erk (Kortenjann et al., 1994; Troppmair et al., 1994) , this observation suggests a critical role for RhoA in the Ras/Raf/Erk signaling pathway.
Despite these observations, much remains to be learned regarding the role of Rho proteins in cell proliferation control. For example, within the Rho subfamily, the most studied members of which are RhoA, B, and C, most analyses have focused on serum-induced proliferation in ®broblasts. It is unclear whether Rho is required for proliferation independently of serum, or in cell types other than ®broblasts, such as in epithelial cells from which most human cancers are derived. Moreover, even in ®broblasts, the mechanisms by which Rho promotes transformation and cell cycle progression are not well understood.
p21
CIP1/WAF1/SID1 in Swiss 3T3 ®broblasts (Olson et al., 1998) . Speci®cally, RhoA was needed to suppress the inhibitory levels of p21 CIP1 that are otherwise induced in response to oncogenic Ras (Olson et al., 1998; Woods et al., 1997) . It is not known whether p21 CIP1 is also a target for Rho in non-transformed cells. However, as p21 CIP1 is induced transiently during G1 progression in numerous cell types (Gudas et al., 1995; Li et al., 1994; Macleod et al., 1995; Michieli et al., 1994) , a mechanism to suppress p21 CIP1 expression prior to S phase entry may be of general importance for cell cycle progression in response to serum and growth factor stimulation.
In previous work, we found that the transient expression of p21 CIP1 was particularly well de®ned in EGF-stimulated MCF10A mammary epithelial cells (Liberto and Cobrinik, 2000) . Since EGF is both necessary and sucient for serum-independent proliferation in MCF10A cells, this system allowed us to examine the requirement for Rho in cell cycle progression induced by a single factor, EGF, apart from the complicating interactions of unde®ned serum components or multiple mitogens. We found that Rho was required for EGF to induce S phase entry, and in particular for the repression of p21 CIP1 in EGFstimulated cells. We also found that Rho induces cyclin D1 promoter activity and oncogenic Rasdependent proliferation and that these two eects of Rho occur in conjunction with defects in the G2 replication checkpoint in cells expressing oncogenic Ras. Our results demonstrate that Rho plays a fundamental role in mitogenic signaling by both growth factor and oncogenic Ras-dependent pathways, and establish the cell cycle regulatory proteins p21 CIP1 and cyclin D1 as targets for Rho in promoting DNA synthesis in mammary epithelial cells.
Results

Rho is required for EGF-induced S phase entry
MCF10A cells do not require serum, but instead rely on the mitogenic signals provided by EGF for G1 progression and entry into S phase (Soule et al., 1990) . To test whether Rho subfamily proteins are required for EGF-induced DNA synthesis in exponentially growing cells, we inhibited endogenous RhoA, B and C with the bacterial protein, C3 exotransferase (Aktories and Just, 1995) . C3 exotransferase was used instead of dominant negative Rho (RhoN19) because we found that although the two give qualitatively similar results, C3 is a more dramatic inhibitor than RhoN19 (data not shown). Cells were cotransfected with a plasmid containing GFP and a fourfold excess of either empty vector or a C3 exotransferase expression vector. Following transfection, cells were cultured in serum free media with or without EGF for 24 h. Cycling cells were labeled with BrdU during the last 16 h of culture and detected by indirect immuno¯uor-escence using a BrdU speci®c antibody. After 24 h of EGF deprivation, approximately 10% of the transfected cells had incorporated BrdU (Figure 1a ). However, this low level of BrdU incorporation depended on the earlier EGF signal, since EGF deprivation for an additional 24 h resulted in 0% BrdU incorporation (data not shown). In EGF stimulated cells, 22% of C3 transfected cells were BrdU positive, compared to 68% of vector transfected cells, indicating that Rho signaling is important for EGF-dependent DNA synthesis in MCF10A cells (Figure 1a) .
To determine whether C3 induced a G1-or G2-speci®c arrest associated with inhibition of DNA synthesis, we used two-color¯ow cytometry to examine the DNA distribution of GFP positive cells. Cells were cotransfected with GFP and C3 as in the previous experiment and then cultured in serum-free media containing EGF for 20 h. Under these conditions, about 16% of vector transfected cells were in S phase and about 17% were in G2 or mitosis (Figure 1b) . For cells transfected with C3, the S phase fraction was reduced by 80% (from 16 to 3%). This reduction in S phase cells was accompanied by a reduction in the percentage of cells in G2 and mitosis as well as an accumulation of cells in G1 phase. These results indicated that in the absence of serum, Rho was required for EGF-dependent passage through G1 and entry into S in MCF10A cells.
Rho is required for repression of p21 CIP1 in asynchronously growing MCF10A cells A recent study demonstrated that Rho was required for oncogenic Ras-induced DNA synthesis in Swiss 3T3 cells speci®cally because Rho was needed to suppress the inhibitory levels of p21 CIP1 that are otherwise induced by oncogenic Ras (Olson et al., 1998; Woods et al., 1997) . Currently, it is not known if this regulation of p21 CIP1 by Rho is unique to cells expressing oncogenic Ras, or whether it is a general aspect of Rho-dependent signaling. Thus, we examined whether Rho regulates p21 CIP1 as part of a cellular mitogenic response.
We ®rst examined the eect of the Rho inhibitor, C3 exotransferase, on p21 CIP1 levels in cells that were cultured continuously with EGF. p21 CIP1 was detected by indirect immuno¯uorescence in cells that were cotransfected with a GFP expression plasmid and a fourfold excess of a plasmid encoding C3. Camptothecin treatment, which induces both p21 CIP1 and p53 proteins and a G1 arrest in MCF10A cells (unpublished results), was used as a positive control for p21 CIP1 and served as a benchmark for the visual quanti®cation of p21 CIP1 -positive nuclei in these experiments. Whereas p21 CIP1 was detected in only a small minority of the cycling cells, C3 dramatically induced p21 CIP1 expression (Figure 2 ). This implies that Rho-dependent signaling was crucial for maintaining low levels of p21 CIP1 in cells that were growing in the presence of EGF. Rho may also have a role in maintaining low basal expression of p21 CIP1 since C3 modestly increased p21 CIP1 expression in cells that were grown in the absence of EGF (Figure 2) .
We next examined whether Rho was also required for the down-regulation of p21 CIP1 during G1 progression in acutely stimulated cells. EGF stimulation of quiescent MCF10A cells was previously shown to induce a dramatic, transient increase in p21 CIP1 that is maximal after 2 h and then subsides to low basal expression levels for the remainder of G1 and S phase (Liberto and Cobrinik, 2000) . To test whether Rho was required for this down-regulation of p21 CIP1 , we examined p21 CIP1 expression in cells that had been cotransfected with C3 together with GFP to identify transfected cells. Following transfection, the cells were starved for 24 h in serum-and EGF-free media, and then were either restimulated with EGF for 2 or 4 h, or left unstimulated. In vector transfected cells, EGF stimulation resulted in a striking increase in the proportion of p21 CIP1 positive nuclei to about 40% by 2 h, followed by a return to basal levels by 4 h ( Figure  3 ). This dramatic transient response is consistent with Western analysis of p21 CIP1 expression under the same conditions (Liberto and Cobrinik, 2000) . C3 did not aect the induction of p21 CIP1 by EGF, but signi®cantly impaired p21
CIP1 down-regulation (P-value50.01, Student's t-test), implying that Rho is important for the decline in p21 CIP1 during G1-S progression. We also tested whether ectopic Rho activity was sucient to impair the induction of p21 CIP1 by EGF by transfection of the constitutively active mutant, V14RhoA. However, as shown in Figure 3 , V14RhoA only modestly reduced the EGF-dependent accumulation of p21
CIP1 at 2 h (P-value=0.05, Student's t-test). Thus, although Rho was important for repression of p21 CIP1 during G1 progression, constitutive Rho signaling had only a minor eect on early p21
CIP1 induction. Finally, we tested the eect of C3 on cells that were cultured without EGF for 24 h, to determine if Rho was also needed to repress p21 CIP1 in cells that have exited the cell cycle. In EGF-starved cells there was a low but detectable expression of p21 CIP1 . C3 induced p21 CIP1 in these quiescent cells (Figure 2 ), but this induction was modest compared to its eect in cycling, EGF-stimulated cells. These data indicate that the low basal expression of p21 CIP1 in quiescent cells depended only to a minor extent on repression by Rho. In contrast, Rho played a substantial role in the repression of p21 CIP1 in EGF-stimulated cells.
Rho is required for EGF-induced activation of the cyclin D1 promoter and is sufficient to induce cyclin D1 promoter activity
The constitutively active mutant, V14RhoA, was earlier shown to induce S phase entry in serum-starved ®broblasts (Olson et al., 1995) , indicating that V14RhoA was sucient for S phase entry in these cells. It seems unlikely that the repression of p21 CIP1 alone would be sucient for S phase entry without the induction of G1 cyclins. EGF strongly induced cyclin D1 expression in MCF10A cells (Liberto and Cobrinik 2000) , and others have shown that cyclin D1 is particularly important for the proliferation of adult mammary epithelial cells in vivo (Sicinski and Weinberg, 1997) . We therefore examined whether Rho was required for EGF to induce cyclin D1 promoter activity in MCF10A cells. Transfected cells were cultured for 24 h in growth factor-free media and cyclin D1 promoter activity was measured either in growth factor-free conditions or following 4 h stimulation with EGF. As shown in Figure 4a , EGF induced cyclin D1 promoter activity by ®vefold. However, C3 completely blocked EGF-induced cyclin D1 promoter activity. Furthermore, ectopically expressed V14RhoA activated the cyclin D1 promoter in growth factor-free media. Strikingly, while V14RhoA along with EGF stimulated cyclin D1 promoter activity more than threefold over that of EGF alone, this activity was only slightly greater than that induced by Rho in the absence of EGF. Taken together, our results suggested that the EGF-dependent induction of cyclin D1 was occurring largely through RhoA. Whereas others have also shown that ectopic V14RhoA expression was able to induce cyclin D1 expression (Westwick et al., 1997) , this is the ®rst indication that Rho signaling is required for cyclin D1 expression in growth factor-stimulated cells.
To further explore the induction of the cyclin D1 promoter by Rho, we examined the eects of V14RhoA on the activity of the cyclin D1 promoter in asynchronously growing cells cultured with EGF ( Figure 4b ). As in acutely stimulated cells, Rho stimulated cyclin D1 transcriptional activity. In fact, V14RhoA stimulated the cyclin D1 promoter to a greater extent than RacV12, which was previously reported to be an activator of cyclin D1 transcription (Joyce et al., 1999; Page et al., 1999) . Since the Rho eector protein, Roka, was reported to be required for the transforming activity of Rho (Sahai et al., 1999) , we tested whether ectopic Roka activated the cyclin D1 promoter. However, transfection of a plasmid encoding Roka did not aect cyclin D1 activation by EGF, nor did co-transfection of Roka with V14RhoA have a synergistic eect, suggesting that Roka expression was not limiting for Rho activation of cyclin D1 in these cells.
Rho is required for oncogenic Ras to induce S phase entry and for the repression of p21 CIP1 in V12Ras-expressing cells
The studies described above showed that Rho was required for EGF-induced S phase entry in MCF10A Figure 3 Eects of Rho on EGF-dependent p21 CIP1 expression during G1 phase. Cells were cotransfected with plasmids encoding GFP and either V14RhoA, C3 or empty vector. Transfected cells were cultured without EGF in serum free media for 24 h followed by stimulation with 5 ng/ml for 2 or 4 h. Expression of p21 cells. Since EGF-induced DNA synthesis depends on the Ras/Erk pathway in these cells (Figure 5a ), we examined whether Rho was also required for oncogenic Ras to induce entry into S, independent of other EGFinduced signals. Cells were cotransfected with a plasmid encoding GFP along with either empty vector or plasmids encoding constitutively active mutants of Ras (V12Ras) and either in the presence of absence of the Rho inhibitor C3. Following transfection, the cells were starved for 24 h in serum-and growth factor-free media, and then analysed for DNA content by¯ow cytometry. As shown in Figure 6b ± d, V12Ras greatly increased the percentage of S phase cells, and this eect was completely blocked by C3 (Figure 5b ). In contrast to the eects of RasV12, the constitutively active V14RhoA was only slightly mitogenic ( Figure 5c ). However, the combination of V14RhoA and V12Ras approximately doubled the percentage of cells in S phase as compared to Ras alone (Figure 5d ), demonstrating that RhoA synergizes with V12Ras to promote S phase entry. Together with our earlier data, these results indicated that RhoA may be a fundamental component of a Ras-dependent mitogenic signal, whether induced by EGF or by ectopic expression of constitutively active V12Ras. We next explored the mechanism by which Rho promoted Ras-induced DNA synthesis. In particular, we examined whether Rho also suppressed p21 CIP1 in oncogenic Ras-expressing MCF10A cells, as it had in EGF-stimulated MCF10A cells and in Ras transformed ®broblasts. To do this, cells were cotransfected with a bicistronic vector encoding V12Ras and GFP, together with a ®vefold excess of either C3 or the empty vector. Transfected cells were then cultured for 24 h in serum free media and p21 CIP1 was detected by indirect immuno¯uorescence. As shown in Figure 6a , the low basal expression of p21 CIP1 in quiescent cells was modestly increased by expression of C3 or V12Ras alone, but was substantially increased by co-expression of C3 and V12Ras. These results indicated that Rho had little eect on p21 CIP1 expression except in the presence of active Ras, consistent with our earlier ®ndings using quiescent and EGF-stimulated cells.
Furthermore, under conditions where there was relatively little cyclin D1 promoter activity due to V12Ras alone, there was a signi®cant induction of the promoter in cells co-expressing V12Ras and V14RhoA (Figure 6b ). These data suggest that there may be a general requirement for Rho to cooperate with Ras both for the repression of p21 CIP1 and the induction of cyclin D1.
Transient expression of V12Ras and V14RhoA results in replication checkpoint defects
While co-expression of V14RhoA and V12Ras led to an increase in the number of cells in S phase (Figure 5d ), this combination also resulted in a striking nuclear phenotype that suggested a defect in the regulation of DNA synthesis and mitosis (Figure 7a ). About 22%+1, (n=3) of cells that were cotransfected with Ras and Rho were abnormally large and contained multilobulated nuclei. We con®rmed that approximately 71%+6 (n=2) of these lobulated nuclei were actively synthesizing DNA, as shown by their incorporation of BrdU (Figure 7b) . Furthermore, when cells co-expressing V12Ras and V14Rho were cultured for 4 days in serum free media, there was a sevenfold increase in cells having greater than diploid DNA content compared to cells expressing either empty vector or Ras alone (data not shown). Thus, a signi®cant fraction of cells coexpressing Ras and Rho underwent DNA synthesis that was uncoupled from mitosis. Previously it was shown Figure 4 Cyclin D1 promoter activity is induced by V14RhoA and inhibited by C3 exotransferase. (a) Cells were transfected with 0.5 mg of a cyclin D1 luciferase reporter construct and 0.01 mg of a control reporter plasmid along with 1 mg of the indicated expression plasmid then cultured in serum free, growth factor free media for 24 h. Luciferase activity was measured in lysates taken from cells that were either stimulated with EGF for 4 h or left unstimulated, as indicated. Activity is shown relative to that of vector transfected cells in serum free media, pcDNA3=1.0. (b) Cells were transfected as in a except the total amount of DNA was brought to 2.5 mg with empty vector to compensate for the increased DNA in cotransfections of Rho and Rok (1 mg each). Following transfection, the cells were cultured for an additional 24 h in media containing EGF. Activity is shown relative to that of vector transfected cells cultured with EGF, pcDNA3=1.0. For both a and b, bars indicate average values of the cyclin D1 promoter luciferase activity normalized to that of the internal control promoter, +s.e.m., n=3 that p21 CIP1 was required for the G2 checkpoint that ensures that a single duplication of the genome is followed by chromosome segregation and mitosis (Dulic et al., 1998; Niculescu et al., 1998; Stewart et al., 1999) . Accordingly, our ®ndings suggest that Rho-mediated repression of p21 CIP1 , perhaps in combination with Rho-mediated induction of cyclin D1, impairs the checkpoint that prevents the reinitiation of S phase until the completion of mitosis.
Discussion
We show here that Rho is required for S phase entry both in response to EGF and in response to oncogenic Ras in MCF10A mammary epithelial cells, and that Rho is important for the appropriate expression of the G1 cell cycle regulators, p21 CIP1 and cyclin D1. Our ®nding that Rho regulates p21 CIP1 expression in epithelial cells responding to the mitogenic signal of EGF is the ®rst demonstration of p21 CIP1 regulation by Rho in the absence of an oncogenic signal, and suggests that Rho may mediate the repression of p21 CIP1 that is commonly seen during G1 progression. We also show that Rho signaling is both sucient to induce cyclin D1 transcriptional activity, and is required for EGF to induce cyclin D1 promoter activity in these cells. Finally, we provide evidence for the loss of replication checkpoint control in cells co-expressing activated Rho and oncogenic Ras.
Previously, Rho was shown to be required for serum-induced DNA synthesis in ®broblasts (Yamamoto et al., 1993) . Here we show that Rho also regulates EGF-induced DNA synthesis, independently of serum, in mammary epithelial cells, and that Rho suppresses the expression of p21 CIP1 in EGF-stimulated, but not in quiescent cells. This was in addition to a requirement for Rho to repress p21 CIP1 in MCF10A cells expressing oncogenic Ras (V12Ras). Since Rho was required for p21 CIP1 repression in ®broblasts expressing V12Ras (Olson et al., 1998) , it was not surprising that Rho was also required to repress p21 CIP1 in V12Ras expressing MCF10A cells. However, it is notable that Rho was also required for the repression of p21 CIP1 in growth factor-stimulated cells, since constitutively active Ras initiates signaling pathways that dier from those of cellular Ras (Kerkho and Rapp, 1998a,b; Marshall, 1995; Tombes et al., 1998) . Our results suggest that the regulation of p21 CIP1 by Rho may be a general feature of Ras-mediated mitogenic signaling, whether induced by growth factor stimulation or by oncogenic Ras expression.
In addition to repressing p21 CIP1 , we found that Rho positively regulates cyclin D1 expression. This was indicated by its requirement for EGF-induced activation of the cyclin D1 promoter and by the ability of V14RhoA to induce cyclin D1 promoter activity in serum-and EGF-free media. This is the ®rst indication that Rho signaling is both necessary and sucient for cyclin D1 induction in non-transformed cells. The ability of Rho to promote cyclin D1 expression may have substantial relevance to mammary tumorigenesis, since cyclin D1 is over-expressed in at least 50% of human mammary carcinomas (Bartkova et al., 1994; Gillett et al., 1994) , and is required for oncogenic Neu and Ras-induced mammary tumorigenesis in mice (Yu et al., 2001) . In addition, it is notable that Neu and Ras target the cyclin D1 promoter (Albanese et al., 1995; Lee et al., 2000) , and that RhoA has been implicated as functioning downstream of Neu in the induction of cyclin D1 in MCF7 breast cancer cells (Lee et al., 2000) . Our ®nding that Rho is necessary and sucient for cyclin D1 induction in non-transformed MCF10A cells supports the idea that the regulation of the cyclin D1 promoter by Rho is generally important for the response of breast epithelial cells to Ras signaling.
It was striking that Rho was required for two distinct, and potentially powerful eects on G1 cell cycle regulators. This provokes the question as to whether the induction of cyclin D1 and repression of p21 CIP1 are independent consequences of Rho signaling, or alternatively, if these eects are mechanistically related to one another. In support of there being a related mechanism for the regulation of cyclin D1 and p21 CIP1 , we previously showed that under the conditions used here, cyclin D1 protein reaches maximal levels between 2 and 4 h after EGF stimulation, precisely coinciding with the decline in p21 CIP1 (Liberto and Cobrinik, 2000) . This suggests that Rho might be required for the induction of cyclin D1 within the initial 2 h of EGF stimulation and that the accumulation of cyclin D/CDK complexes may then target p21 CIP1 for degradation, in a manner similar to the targeted degradation of p27 KIP1 by cyclin E/CDK2 (Pagano et al., 1995) . If the Rho-dependent induction of cyclin D1 was indeed needed prior to down regulation of p21 CIP1 , then this might also account for the failure of V14RhoA to repress the initial expression of p21 CIP1 , immediately following EGF stimulation. However, further experiments are required to test this hypothesis.
In addition to characterizing changes in G1 cell cycle regulators, our results also demonstrated a previously uncharacterized defect in replication control as a consequence of elevated Rho activity in cells expressing oncogenic Ras. A signi®cant proportion of cells cotransfected with V12Ras and V14Rho were characterized by a lobulated nuclear phenotype in which DNA synthesis continued in the apparent absence of mitosis. Following several days of culture in serumand EGF-free media, these cells showed a substantial increase in ploidy over cells transfected with V12Ras alone. A similar nuclear phenotype was observed in p21 CIP1 -null tumor cells that had been treated with DNA damaging agents, but not in corresponding p21 CIP1 positive cells (Waldman et al., 1996) . This is consistent with the recently characterized role for p21 CIP1 in regulating a G2 checkpoint that protects against endoreduplication (Mantel et al., 1999; Niculescu et al., 1998; Stewart et al., 1999) . Furthermore, over-expression of cyclin D1 and an associated loss of G1-S checkpoint control increased genomic instability as measured by gene ampli®cation in a rat epithelial cell line (Zhou et al., 1996) . Thus, our results suggest that Rho may contribute to genomic instability in V12Ras-expressing cells through its abilities both to repress p21 CIP1 and to induce cyclin D1 expression. Our observation that oncogenic Ras and constitutively active Rho promote a deformed nuclear architecture and increased ploidy in MCF10A cells suggests that in tumors, the combined activation of Ras and Rho might promote chromosomal instability. Activating Ras mutations occur in a signi®cant fraction of human tumors (Barbacid, 1987) . Although Rho itself is not known to be a human oncogene, members of the Dbl family of Rho activating proteins are highly oncogenic (Cerione and Zheng, 1996) . Dbl proteins are guanine nucleotide exchange factors for Rho, Rac, and Cdc42, initially identi®ed in human B-cell lymphomas and also found in a number of other malignancies (Eva and Aaronson, 1985; Ron et al., 1988) . The transforming ability of Dbl is mediated through all three Rho subfamilies, and fast-cycling mutants of the Rho proteins are individually able to promote tumor formation as eciently as Dbl itself (Lin et al., 1999) . Furthermore, the only activity tested that correlated with the transforming potential of individual Dbl family members was the ability to activate the cyclin D1 promoter (Westwick et al., 1998) . Thus, if Rho is constitutively activated in cells that also have activating Ras mutations, then this combination could be a causative factor in the genomic instability which is a common feature of cancer cells.
In summary, this study had shown that Rho has several eects on cell cycle control proteins that may be relevant to mammary tumorigenesis. In non-transformed mammary epithelial cells, Rho has a crucial role in EGF-induced and Ras-induced cell cycle progression and appears to act, at least in part, by inducing cyclin D1 and repressing p21 CIP1 expression. Through these and perhaps other eects, Rho may contribute to the genomic instability of cancer cells. Because of this, Rho is an attractive molecular target for cancer therapy or prevention. Agents that inhibit Rho may be expected to repress cyclin D1, increase Ras-dependent p21 CIP1 expression, and thereby promote normal replication control in cells that express oncogenic Ras. We previously found that putative chemopreventive compounds in green tea had exactly the eects that would be expected of a Rho inhibitor, as the polyphenolic compound epigallocatechin gallate (EGCG) strongly prevented both the induction of cyclin D1 and the repression of p21 CIP1 following MCF10A stimulation with EGF (Liberto and Cobrinik, 2000) . Accordingly, it will be of interest to determine if EGCG and related compounds inhibit Rho signaling, and whether their eect on Rho signaling contributes to cancer chemoprevention.
Materials and methods
Plasmids
The pIRES ± V12Ras plasmid was constructed by subcloning an EcoRI fragment of pSRa ± Myc ± V12Ras into the pIRES2 ± EGFP vector (Clontech). To obtain the C3 transferase ± GFP fusion protein, a 1 kb EcoRI ± ApaI fragment of pRcCMV ± C3 transferase was cloned into the pEGFP expression vector. The cDNAs for constitutively active Rac1 (pEXV ± Myc ± V12Rac1) and RhoA (pEXV ± Myc ± V14RhoA) are described in (Minden et al., 1995) . The V12Rac1 and V14RhoA plasmids used here were obtained by subcloning an EcoRI fragment of the pEXV construct into the pSRa or pCDNA3 expression vector, respectively. The full-length cyclin D1 reporter (71745CD1LUC) was a gift from RG Pestell. The plasmid encoding the wild-type Rhokinase (Roka) was a gift from R Prywes. The expression vector encoding farnesylated GFP was from Clontech.
Cell culture
MCF10A cells were maintained in DMEM : F12 (1 : 1) supplemented with 5% heat inactivated horse serum, 4 mM L-glutamine, 100 mg/ml penicillin/streptomycin, 20 mM HEPES, 10 mg/ml insulin, 0.50 mg/ml hydrocortisone, 0.10 mg/ml cholera toxin, and 0.02 mg/ml EGF. All experiments, including transfections, were performed in a serum free media that consisted of DMEM : F12 (1 : 1) with 4 mM Lglutamine, 20 mM HEPES, 1 mg/ml BSA, 5 mg/ml transfer-rin, 0.02 mg/ml sodium selenite, and 1 mg/ml hydrocortisone. Where indicated, EGF (5 ng/ml) was added to this media to induce or maintain proliferation. For experiments requiring immuno¯uorescence detection methods, the cells were plated on glass cover slips at an appropriate density the day before transfection.
Transfections
Cells were transfected with FuGene TM 6 (Roche) according to the manufacturer's protocols. For¯ow cytometry and immuno¯uorescence detection, cotransfections were done with at least a 4 : 1 excess of the appropriate plasmid along with a plasmid encoding a farnesylated green¯uorescent protein (Clontech). For immuno¯uorescence analysis of oncogenic Ras, the GFP was omitted, since Ras was cloned into a pIRES ± EGFP vector. It should also be noted that, although the C3 construct used here was a GFP fusion, the green¯uorescence of the fusion protein was too dim for easy detection, so GFP was also cotransfected with C3 in all experiments.
Flow cytometry
Cells were ®xed in 70% ethanol for 30 min followed by incubation in a solution of 10 mg/ml propidium iodide containing 50 mg/ml Rnase A at 378C for 30 min. Detection of GFP positive cells and DNA content was performed on a FacsCalibur TM workstation (Becton Dickinson) using CellQuest TM software for acquisition and¯uorescence compensation. Ten to ®fteen thousand single gated, GFP positive events were collected for each sample. Mod®t TM software was used for analysis of DNA content. For all experiments, the S phase population was modeled based on those cells having DNA content between 2N and 4N, and for all results reported here, the ®t of the data to the model used was good, de®ned as values between 0.9 ± 3.0 for the reduced chi square (RCS) statistic. It should be noted that due to the presence of a signi®cant polyploid population in Rho : Ras cotransfected cells, the S phase determination for these cells is likely to have been an underestimate.
BrdU labeling and detection
The labeling solution consisted of 30 mM 5-bromo-2-deoxyuridine-5-monophosphate, 30 mM 2-deoxycytidine, and 10 mM 5-¯uorodeoxyuridine. Cells were ®xed in 4% paraformaldehyde (PFA) for 10 min followed by permeabilization with 70% ethanol and treatment with DnaseI (Sigma) at 308C for 20 min. After blocking in 5% goat serum, cover slips were incubated with a monoclonal antibody against BrdU (Boehringer-Mannheim) for 60 min followed by incubation with a rhodamine conjugated goat anti-mouse secondary antibody (Pierce) in a solution containing 1 mg/ml 4',6-diamidine-2-phenylindol dihydrochloride (DAPI).
Immunodetection of p21 CIP1
Cells were ®xed in 4% PFA followed by a 5 min incubation in PBS containing 0.5 M glycine, then permeabilized by submersion in an ice-cold solution of methanol : acetone (1 : 1) for 2 min. Nonspeci®c binding sites were blocked by incubation with 5% goat serum in PBS containing 0.5% Tween-20 for 20 min. A mouse monoclonal antibody against p21 CIP1 (DCS-60.2, NeoMarkers) was diluted 1 : 100 in blocking solution and incubated with the coverslips for 1 h. The signal was ampli®ed using a secondary antibody conjugated to biotin (6 ml/ml) followed by incubation with a solution of rhodamine conjugated avidin (2 ml/ml). Three PBS washes were done after each antibody incubation and following the ®nal incubation with avidin. For visualization of polymerized actin, either¯uorescein or rhodamine conjugated phallotoxins were included in the ®nal incubation (1 : 20). If nuclear morphology was to be detected, DAPI was also included with the ®nal incubation (40 mg/ml).
Cell counting
For quantitation of BrdU incorporation or p21 CIP1 , at least 100 GFP positive cells were counted for each transfection. The ®elds used for counting were sampled in a grid pattern to obtain an even distribution across the coverslip. Each coverslip was counted at least twice to obtain an average value for a given experiment. Two or three independent experiments were performed for each quantitation, as indicated in ®gure legends.
